Protypia, Inc.'S Acquisition By Inotiv, Inc. Broadens The Company's Protein/Peptide Bioanalytical Capabilities

The likelihood of success for compounds entering late-stage clinical development will increase with patient segmentation.

FREMONT, CA: Protypia, Inc., a company based in Nashville, Tennessee, is acquired by Inotiv, Inc. (the "Company," "We," or "Our," or "Inotiv"). Leading nonclinical and analytical drug discovery and development services, research models, and associated goods and services are the focus of Inotiv, Inc., a contract research business. This top contract research organization specializes in nonclinical and analytical drug discovery and development services, research models, and related products and services. Protypia is an up-and-coming protein/peptide bioanalytical firm providing high-quality, tissue-based peptide mass spectrometry and protein.

"This highly-specialized technology and know-how significantly enhances our ability to support clients in the development of safe and effective medicines, particularly in the areas of immuno-oncology and cell and gene therapy. 

The ability to precisely quantify protein levels in tissues, including paraffin-embedded tissues, opens exciting new avenues for scientists to explore as they investigate disease pathways." says John Sagartz, Chief Strategy Officer of Inotiv.

The estimated $11.0 million transactions were roughly $9.5 million in cash, approximately $0.9 million worth of Inotiv common shares, and $0.6 million in unsecured subordinated promissory notes. The business plans to keep all current Protypia personnel on board and continue business in Nashville, Tennessee. The Company's products and services are designed to speed up, improve data quality, and lower the price of bringing novel medicines to market while advancing the development of new medications and medical devices through the discovery and preclinical stages.

Inotiv is dedicated to assisting researchers in realizing the full potential of their important R&D projects while supporting their goals for discovery and development. All of this is done while collaborating to create a safer and healthier society.